Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
University of Lübeck · University Hospital Schleswig-Holstein · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,958
total citations
- FWCI
- 134.36
- Percentile
- 100%
- References
- 14
Citations per year
Authors
21- AHAxel HauschildCorresponding
University of Lübeck, University Hospital Schleswig-Holstein
- JGJean‐Jacques Grob
Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université
- LDLev Demidov
Russian Cancer Research Center NN Blokhin
- TJThomas Jouary
Hôpital Saint-André
- RGRalf Gutzmer
Medizinische Hochschule Hannover
Topics & keywords
Topics
Keywords
- Dabrafenib
- Dacarbazine
- Medicine
- Internal medicine
- Melanoma
- Hazard ratio
- Clinical endpoint
- Adverse effect
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.